TW200640466A - Method of treatment - Google Patents
Method of treatmentInfo
- Publication number
- TW200640466A TW200640466A TW095100687A TW95100687A TW200640466A TW 200640466 A TW200640466 A TW 200640466A TW 095100687 A TW095100687 A TW 095100687A TW 95100687 A TW95100687 A TW 95100687A TW 200640466 A TW200640466 A TW 200640466A
- Authority
- TW
- Taiwan
- Prior art keywords
- related disorders
- disorders
- substance
- pharmaceutically acceptable
- limited
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64226205P | 2005-01-07 | 2005-01-07 | |
US73786405P | 2005-11-18 | 2005-11-18 | |
US73786505P | 2005-11-18 | 2005-11-18 | |
US73788705P | 2005-11-18 | 2005-11-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200640466A true TW200640466A (en) | 2006-12-01 |
Family
ID=36647771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW095100687A TW200640466A (en) | 2005-01-07 | 2006-01-06 | Method of treatment |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1838325A1 (es) |
JP (1) | JP2008526839A (es) |
AR (1) | AR052191A1 (es) |
TW (1) | TW200640466A (es) |
UY (1) | UY29326A1 (es) |
WO (1) | WO2006073360A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090069292A1 (en) * | 2005-11-18 | 2009-03-12 | Astrazeneca Ab | Liquid Formulations |
ME01516B (me) | 2008-06-20 | 2014-04-20 | Astrazeneca Ab | DERIVAT DIBENZOTIAZEPINA l NJEGOVA UPOTREBA |
US8389716B2 (en) | 2009-01-30 | 2013-03-05 | F.I.S. Fabbrica Italiana Sintetici S.P.A. | Process for the synthesis of quetiapine |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3539573A (en) * | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
GB8607684D0 (en) * | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
US7071133B2 (en) * | 1993-11-16 | 2006-07-04 | Ppg Industries Ohio, Inc. | Colored glass compositions and-automotive vision panels with-reduced transmitted-color shift |
US5602124A (en) * | 1994-12-12 | 1997-02-11 | Allelix Biopharmaceuticals, Inc. | 5-HT2 receptor ligands |
SE0003126D0 (sv) * | 2000-09-05 | 2000-09-05 | Astrazeneca Ab | Method of treatment |
JP2004518699A (ja) * | 2001-02-06 | 2004-06-24 | アストラゼネカ・アクチエボラーグ | クエチアピンを用いた物質乱用の治療方法 |
EP1578428A4 (en) * | 2002-10-18 | 2008-11-26 | Massachusetts Mental Health In | TREATMENT OF ALCOHOL OR DRUG ABUSE BY ANTAGONIZING ALPHA-A2 DRENERGEN RECEPTORS WITH SWITCHING DOPAMINE BLOCKING |
CN1816339B (zh) * | 2003-07-02 | 2010-12-15 | 阿斯利康(瑞典)有限公司 | 喹硫平的代谢物 |
WO2005053619A2 (en) * | 2003-12-04 | 2005-06-16 | The Research Foundation Of The City University Of New York | Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal |
SI1696931T1 (sl) * | 2003-12-22 | 2009-08-31 | Acadia Pharm Inc | Amino substituirani diaril(a,d)cikloheptenski analogi kot muskarinski agonisti in postopki za zdravljenje nevropsihiatričnih motenj |
US20050171088A1 (en) * | 2004-01-30 | 2005-08-04 | Astrazeneca Ab | Treatment of psychoses with dibenzothiazepine antipsychotic |
-
2006
- 2006-01-04 JP JP2007550327A patent/JP2008526839A/ja active Pending
- 2006-01-04 EP EP06700349A patent/EP1838325A1/en not_active Withdrawn
- 2006-01-04 WO PCT/SE2006/000009 patent/WO2006073360A1/en active Application Filing
- 2006-01-05 UY UY29326A patent/UY29326A1/es not_active Application Discontinuation
- 2006-01-06 AR ARP060100058A patent/AR052191A1/es not_active Application Discontinuation
- 2006-01-06 TW TW095100687A patent/TW200640466A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
UY29326A1 (es) | 2006-08-31 |
JP2008526839A (ja) | 2008-07-24 |
AR052191A1 (es) | 2007-03-07 |
EP1838325A1 (en) | 2007-10-03 |
WO2006073360A1 (en) | 2006-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006060507A3 (en) | Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders | |
WO2004032836A3 (en) | Antidiabetic beta-amino heterocylcic dipeptidyl peptidase inhibitors | |
MA28469B1 (fr) | Inhibiteurs de la dipeptidyle peptidase | |
EP2338490A3 (en) | Combinations useful for the treatment of neuronal disorders | |
WO2007041365A3 (en) | 3-cyclyl-2- (4-sulfamo yl-phenyl) -n-cyclyl-propionamide derivatives useful in the treatment of impaired glucose tolerance and diabetes | |
HK1117083A1 (en) | Compositions and methods for treatment of eye disorders | |
WO2004037169A3 (en) | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | |
WO2006017673A3 (en) | Taj in neuronal function | |
GB0225474D0 (en) | Therapeutic agents | |
WO2007005896A3 (en) | Anti-tubercular drugs: compositions and methods | |
GEP20125565B (en) | Lactam compounds and their pharmaceutical use | |
GB0223038D0 (en) | Therapeutic compounds | |
WO2004071431A3 (en) | Method and composition for treating neurodegenerative disorders | |
TW200640466A (en) | Method of treatment | |
HK1144939A1 (en) | Particulates of a crth2 antagonist crth2 | |
TW200616644A (en) | Medicine for prevention or treatment of diabetes | |
ATE533488T1 (de) | Verfahren und formulierungen zur modulierung von lyn-kinaseaktivität und behandlung assoziierter erkrankungen | |
MXPA05009014A (es) | Antagonistas del receptor ccr-3. | |
DE602004015089D1 (de) | Pyrroloimidazolderivate ,verfahern zu ihrer herstellung, diese enthaltende zusammensetzungen, und ihre verwendung als nootropika | |
DE60036122D1 (de) | Verwendung von eplerenon zur behandlung von restenose | |
TW200503726A (en) | Use of dihydroimidazolones for the treatment of dogs | |
ATE326223T1 (de) | Methode zur behandlung der hyperaktiven blase | |
WO2005007239B1 (es) | Uso de la dapsona como neuroprotector en el infarto cerebral | |
WO2008021432A3 (en) | Compositions and methods for treatment of conditions affecting the nervous system | |
TW200630097A (en) | Methods of using PDE V inhibitors for the treatment of congestive heart failure |